PARP1 and Stroke: To demonstrate their potential in human stroke therapy [4], PARP inhibitors were reported to reduce ROS and RNS production, decrease oxidative DNA damage, protein oxidation, and lipid peroxidation, diminish infarct volume, and improve mitochondrial functions in various animal models regarding hypoglycemia as well as focal and global ischemia [155,186].